NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Inmune BIO Inc. INMB
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$50,000
▲ 257.1% vs FY2024
EPS · FY25
$-1.86
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-165.2%
Net margin · FY25
-91866.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 50,000.00
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 91866 cents on every revenue dollar this year.
Per share
USD -1.86
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-165.2%
Return on equity, FY2025
ROE
Operating margin-94766.0%
Net margin-91866.0%
Return on assets-127.7%
Each USD of equity lost 165 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+35.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−48.9%
+35.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+97.2%
Change, 10 years—
The share count grew 97% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 32.4M
total assets, end of FY2025
Total assetsUSD 32.4M
EquityUSD 23.5M
CashUSD 24.8M
Current ratio3.55×
Equity funds 73% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
·
·
·
·
·
·
·
·
Income tax $B
·
·
·
·
·
·
·
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.86
−2.11
−1.67
−1.52
−1.88
−1.01
−0.75
−1.43
−0.13
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−165.2
−121.2
−61.6
−38.9
−51.0
−38.8
−38.2
−71.8
−4.6
Shares out B
0.03
0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed